News

Affymax has reported that it has informed clinical trial sites to complete treatment of patients in the phase 3 clinical program for the investigational drug, Hematide, by the

Humco Holding Group (Humco) has reported that it is increasing inventories and production capabilities of Humco Cherry Syrup for use in the emergency compounding of an oral suspension

Biovista has reported that BVA-201, a drug targeting Multiple Sclerosis (MS), has shown positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is

Solvay Biologicals has completed the validation for its cell-based production facility following a successful inspection by the Dutch authorities. The company said that the 3,900m2 facility in Weesp

ChemGenex Pharmaceuticals (ChemGenex ) has submitted its New Drug Application (NDA) to the FDA for Omapro (omacetaxine mepesuccinate). Omapro is being developed for the treatment of patients with

NephroGenex has completed patient enrollment in its phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2

Germany-based Merck has acquired Suzhou Taizhu Technology Development Co. (Taizhu), a supplier of effect pigments located in Taicang near Shanghai, China. The acquisition is said to of high

“This latest distribution agreement with AXA Diagnostics marks Rosetta Genomics’ entry into Europe, and we are excited to have AXA as our first partner in this region,” noted

Amarillo Biosciences has announced that a phase 2 study of orally administered interferon-alpha for the prevention of influenza and winter colds has reached the midway point. The study